Medicare is spending a lot more on prescription drugs. In 2024 alone, the U.S. government covered a record $16 billion to Part D plans. But is that a bad thing? In Forbes, contributor Joshua P. Cohen argues the surge is evidence that one of the most consequential Medicare reforms in decades is doing exactly what it was designed to do.
Medicare Is Spending Lots More …
Medicare Part D got some upgrades under the Inflation Reduction Act. It capped Medicare beneficiary out-of-pocket spending to $2,000 annually for medications. Seniors with cancer, HIV, autoimmune disease, or other chronic conditions, the cap fundamentally improved health outcomes. Prescriptions that were once delayed, rationed, or abandoned are now being filled. Adherence is rising. Utilization is increasing. And, medicare spending is up. But the increase is not waste, it’s access.
The Shift Didn’t Eliminate Costs. It Moved Them.
The Part D redesign solved one problem decisively: patients are no longer the shock absorber for runaway drug prices. But it did not make drug costs disappear. Instead, financial responsibility shifted upstream to plans, manufacturers, and the federal government.
For insurers, this creates a new reality. Plans are absorbing a larger share of high-cost drug spending, especially in protected classes like oncology and HIV where coverage is mandatory and price negotiation tools are limited. Plans understand that forecasting costs more accurately is paramount because when utilization outpaces projections, the Centers for Medicare and Medicaid Services (CMS) steps in as a backstop through reconciliation payments. The $16 billion payout in 2024 reflects that mechanism is working as intended.
Higher Utilization Raises the Stakes for Precision
One of the most striking data points in the article comes from oncology. After the initial out-of-pocket cap was introduced, the share of cancer patients with zero-dollar copays jumped to 73 percent, and oncology prescription volumes rose roughly 50 percent year over year. More patients stayed on therapy. More prescriptions moved through the system.
That is a win for patients, but it also magnifies the cost of inefficiency.
When utilization rises across the board, every unnecessary prescription, suboptimal drug choice, duplicative therapy, or missed biosimilar opportunity compounds faster. In a capped-OOP world, the margin for error narrows. Plans cannot rely on cost-sharing to self-regulate demand. Clinical appropriateness becomes the primary cost lever.
Where Optimization Actually Happens
This is where many affordability strategies still break down. Too often, cost containment is pursued downstream through member outreach, formulary friction, or retrospective audits. Those approaches are blunt instruments in a system where adherence is rising by design.
RazorMetrics operates further upstream, where decisions are made and locked in.
By working within normal clinical workflows, RazorMetrics identifies lower-cost, clinically appropriate alternatives and delivers them to physicians making it easy to save patients on drug costs. Recommendations may include therapeutic alternatives, biosimilars, and deprescribing opportunities for medications that are no longer needed.
The result is lower costs, more alignment with preferred drug lists, and more secure access to drugs for beneficiaries.
Affordability Without Abandonment
The Part D redesign has made one thing clear: protecting patients from financial harm improves adherence and health outcomes. The next challenge is ensuring that higher utilization translates into higher value.
As Medicare drug spending rises, the question is no longer whether patients can afford their medications. It is whether every dollar spent reflects the best possible clinical and economic choice.
That is the gap RazorMetrics fills. Not by denying care, delaying treatment, or shifting costs back to members, but by helping plans and physicians optimize therapy before waste enters the system.
Medicare spending more on drugs can be a good thing, but spending smarter is what makes budgets sustainable.
